在乌干达和刚果民主共和国感染恶性疟原虫的葡萄糖-6-磷酸脱氢酶缺乏症儿童中按年龄给药的单剂低剂量伯氨喹的安全性:一项随机、双盲、安慰剂对照、非劣效性试验
该随机双盲安慰剂对照非劣效性试验在乌干达和刚果民主共和国纳入1137名6月龄至11岁感染恶性疟原虫的儿童,评价按年龄给药的单剂低剂量伯氨喹安全性。结果显示,G6PD缺乏组中伯氨喹与安慰剂的重度贫血发生率无显著差异(0.66% vs 0%,差异-0.66%,95%CI -1.96至0.63;p=0.35)。作者认为该药耐受性良好,安全性特征与安慰剂相似。
要点
- 单剂低剂量伯氨喹在G6PD缺乏儿童中重度贫血发生率与安慰剂无显著差异。
- G6PD缺乏组伯氨喹1/151(0.66%)vs 安慰剂0/133(0%),差异-0.66%(95%CI -1.96至0.63;p=0.35)。
- 非G6PD缺乏组伯氨喹1/407(0.25%)vs 安慰剂1/430(0.23%),差异-0.014%(95%CI -0.68至0.65;p=0.97)。
核心结论
- 按年龄给药的单剂低剂量伯氨喹在乌干达和刚果民主共和国感染恶性疟原虫的儿童中耐受性良好,安全性特征与安慰剂相似。
- 这些数据支持在非洲更广泛地实施单剂低剂量伯氨喹。
研究设计与样本
- 在乌干达Mbale区域转诊医院和刚果民主共和国金沙萨Mahidol Oxford研究单位开展的随机、双盲、安慰剂对照、非劣效性试验。
- 纳入6月龄至11岁、急性无并发症恶性疟原虫感染且血红蛋白至少6 g/dL的儿童。
- 按1:1随机分配至单剂低剂量伯氨喹联合蒿甲醚-苯芴醇或双氢青蒿素-哌喹,按体重给药,随机化按年龄和G6PD状态分层。
- G6PD状态通过G6PD c.202T等位基因(G6PD缺乏A-变异的原因)基因分型确定。
- 主要终点为治疗21天内发生重度贫血(血红蛋白<4 g/dL)或伴严重特征的重度贫血(血红蛋白<5 g/dL),按意向性治疗分析。
主要发现
- 无参与者发生重度贫血(血红蛋白<4 g/dL),3例发生伴严重特征的重度贫血(血红蛋白<5 g/dL)。
- G6PD缺乏组:安慰剂组133例中0例(0%)发生伴严重特征的重度贫血,伯氨喹组151例中1例(0.66%)发生,差异-0.66%(95%CI -1.96至0.63;p=0.35)。
- 非G6PD缺乏组:安慰剂组430例中1例(0.23%)发生伴严重特征的重度贫血,伯氨喹组407例中1例(0.25%)发生,差异-0.014%(95%CI -0.68至0.65;p=0.97)。
关键数值与推荐
- 主要终点为治疗21天内发生重度贫血(血红蛋白<4 g/dL)或伴严重特征的重度贫血(血红蛋白<5 g/dL)。
- 非劣效界值为3%,假设安慰剂组发生率为1.5%。
临床怎么用
- 作者认为这些数据支持在非洲更广泛地实施单剂低剂量伯氨喹。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: WHO recommends gametocytocidal, single low-dose primaquine for blocking the transmission of Plasmodium falciparum; however, safety concerns have hampered the implementation of this strategy in sub-Saharan Africa. We aimed to investigate the safety of age-dosed, single low-dose primaquine in children from Uganda and the Democratic Republic of the Congo. METHODS: We conducted this randomised, double-blind, placebo-controlled, non-inferiority trial at the Mbale Regional Referral Hospital, Mbale, Uganda, and the Kinshasa Mahidol Oxford Research Unit, Kinshasa, Democratic Republic of the Congo. Children aged between 6 months and 11 years with acute uncomplicated P falciparum infection and haemoglobin concentrations of at least 6 g/dL were enrolled. Patients were excluded if they had a comorbid illness requiring inpatient treatment, were taking haemolysing drugs for glucose-6-phosphate dehydrogenase (G6PD) deficiency, were allergic to the study drugs, or were enrolled in another clinical trial. G6PD status was defined by genotyping for the G6PD c.202T allele, the cause of the G6PD-deficient A- variant. Participants were randomly assigned (1:1) to receive single low-dose primaquine combined with either artemether-lumefantrine or dihydroartemisinin-piperaquine, dosed by bodyweight. Randomisation was stratified by age and G6PD status. The primary endpoint was the development of profound (haemoglobin <4 g/dL) or severe (haemoglobin <5 g/dL) anaemia with severity features, within 21 days of treatment. Analysis was by intention to treat. The sample size assumed an incidence of 1·5% in the placebo group and a 3% non-inferiority margin. The trial is registered at ISRCTN, 11594437, and is closed to new participants. FINDINGS: Participants were recruited at the Mbale Regional Referral Hospital between Dec 18, 2017, and Oct 7, 2019, and at the Kinshasa Mahidol Oxford Research Unit between July 17, 2017, and Oct 5, 2019. 4620 patients were assessed for eligibility. 3483 participants were excluded, most owing to negative rapid diagnostic test or negative malaria slide (n=2982). 1137 children with a median age of 5 years were enrolled and randomly assigned (286 to the artemether-lumefantrine plus single low-dose primaquine group, 286 to the artemether-lumefantrine plus placebo group, 283 to the dihydroartemisinin-piperaquine plus single low-dose primaquine group, and 282 to the dihydroartemisinin-piperaquine plus placebo group). Genotyping of G6PD identified 239 G6PD-c.202T hemizygous males and 45 G6PD-c.202T homozygous females (defining the G6PD-deficient group), 119 heterozygous females, 418 G6PD-c.202C normal males and 299 G6PD-c.202C normal females (defining the non-G6PD-deficient group), and 17 children of unknown status. 67 patients were lost to follow-up and four patients withdrew during the study-these numbers were similar between groups. No participants developed profound anaemia and three developed severe anaemia: from the G6PD-deficient group, none (0%) of 133 patients who received placebo and one (0·66%) of 151 patients who received primaquine (difference -0·66%, 95% CI -1·96 to 0·63; p=0·35); and from the non-G6PD-deficient group, one (0·23%) of 430 patients who received placebo and one (0·25%) of 407 patients who received primaquine (-0·014%, -0·68 to 0·65; p=0·97). INTERPRETATION: Gametocytocidal, age-dosed, single low-dose primaquine was well tolerated in children from Uganda and the Democratic Republic of the Congo who were infected with P falciparum, and the safety profile of this treatment was similar to that of the placebo. These data support the wider implementation of single low-dose primaquine in Africa. FUNDING: UK Government Department for International Development, UK Medical Research Council, UK National Institute for Health Research, and the Wellcome Trust Joint Global Health Trials Scheme.
引用
- Taylor WR, Olupot-Olupot P, Onyamboko MA, et al. Safety of age-dosed, single low-dose primaquine in children with glucose-6-phosphate dehydrogenase deficiency who are infected with Plasmodium falciparum in Uganda and the Democratic Republic of the Congo: a randomised, double-blind, placebo-controlled, non-inferiority trial. Lancet Infect Dis. 2022. PMID: 36462528. doi:10.1016/S1473-3099(22)00658-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。